PIC/S Resumes Assessment Of Countries Seeking To Join Inspection Scheme; Russian Application Frozen For Now
Executive Summary
As it prepares to celebrate its 50th anniversary, the international Pharmaceutical Inspection Co-operation Scheme has set out its agenda for 2022, which includes revising its PIC/S GMP Guide and developing an inspection “aide memoire” for tissue and cellular therapy products.
You may also be interested in...
Amid US Cough Syrup Findings, Regulators Feel India Needs To Work On Perceptions But Also Make Improvements
In wake of the furore caused by OTC cough syrups made by two small Indian companies, former and current US FDA and MHRA officials say quality-related issues are not specific to India. However, while image management needs some work, manufacturers in the country also need to make further improvements to ensure quality.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Outlook Turns To Marketing Strategy After Scoring EU First For Ophthalmic Bevacizumab
Outlook Therapeutics’ intravitreally injected Lytenava has won the thumbs up from the European Medicines Agency. The company is assessing both direct commercialization of the product and partnering in Europe on a country-by-country basis.